fr 139317 has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebihara, I; Fukui, M; Koide, H; Nakamura, T; Tomino, Y | 1 |
| Ebihara, I; Koide, H; Nakamura, T; Tomino, Y | 1 |
2 other study(ies) available for fr 139317 and Alloxan Diabetes
| Article | Year |
|---|---|
Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli.
Topics: Aging; Animals; Azepines; Blood Pressure; Collagen; Creatinine; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Extracellular Matrix Proteins; Fibroblast Growth Factor 2; Gene Expression; Growth Substances; Indoles; Kidney Glomerulus; Laminin; Male; Platelet-Derived Growth Factor; Proteinuria; Rats; Rats, Sprague-Dawley; Reference Values; RNA, Messenger; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 1995 |
Alteration of growth-related proto-oncogene expression in diabetic glomeruli by a specific endothelin receptor A antagonist.
Topics: Animals; Azepines; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Gene Expression; Indoles; Kidney Glomerulus; Male; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins; Proto-Oncogenes; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1996 |